Loading
A phase 2 trial of Encorafenib, Binimetinib in non-small-cell lung cancer and small-cell lung cancer, run by Pierre Fabre Medicament, active and no longer recruiting.
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05195632 by Pierre Fabre Medicament, with 63 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2024-05-27. Interventions recorded: Encorafenib, Binimetinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pierre Fabre, Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, BRAF V600E-mutant non-small-cell lung cancer, Encorafenib.
Shares Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, BRAF V600E-mutant non-small-cell lung cancer, Encorafenib, Small-molecule kinase inhibitors.
Shares A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pierre Fabre, Non-small-cell lung cancer.
Shares Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, Encorafenib.